Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.
NCCN Guidelines® lists fam-trastuzumab deruxtecan-nxki (ENHERTU) as a treatment option for multiple metastatic solid tumors. aSee the NCCN Guidelines for detailed information. aGC, advanced gastric cancer; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; IHC...
Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.
【注射用ENHERTU作用机制】 fam-trastuzumab deruxtecan-nxki是HER2定向的抗体-药物偶联物。该抗体是人源化抗HER2 IgG1。小分子DXd是拓扑异构酶I抑制剂,通过可裂解的接头与抗体连接。与肿瘤细胞上的HER2结合后,fam-trastuzumab deruxtecan-nx...
1、HER2-阳性转移性乳腺癌(MBC):德曲妥珠单抗(Fam-trastuzumab deruxtecan-nxki)适用于治疗患有不可切除或转移性HER2-阳性乳腺癌症的成年患者,这些患者之前接受过基于抗HER2-的方案,包括在转移环境中,或在新辅助或辅助环境中,并且在完成治疗期间或六个月内出现疾病复发。
德曲妥珠单抗(Fam-trastuzumab deruxtecan-nxki)是一种靶向治疗是针对HER2癌症的抗体-药物偶联物(ADC)。它有两个部分,人源化抗HER-2单克隆抗体和拓扑异构酶抑制剂有效载荷deruxtecan,该药物在多种癌症中显示出有希望的客观缓解率,即表达HER2蛋白的非小细胞肺癌、HER2阳性乳腺癌,这些癌症不能通过手术切除,或者在抗...
别名 Fam-trastuzumab deruxtecan、T-DXd、Trastuzumab deruxtecan + [13] 靶点 HER2 x Top I 作用方式 拮抗剂、抑制剂 作用机制 HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂)、TOP1抑制剂(DNA拓扑异构酶I抑制剂)、ADCC(抗体依赖的细胞毒作用) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [6] 在研适应症 HER2...
Enhertu(fam-trastuzumab deruxtecan-nxki)(Enhertu; AstraZeneca,Daiichi Sankyo)是一种新型抗体-药物偶联物,具有三个成分:人源化抗HER2免疫球蛋白G1单克隆抗体,其氨基酸序列与曲妥珠单抗相同(Herceptin,Genentech);拓扑异构酶1抑制剂有效载荷;和基于四肽的可裂解接头。
Enhertu(fam-trastuzumab deruxtecan-nxki) 是一种无菌、白色至黄白色、不含防腐剂的单剂量瓶装冻干粉。每个小瓶输送100毫克fam-trastuzumab deruxtecan-nxki。这是一种抗体-药物缀合物(ADC ),由三种成分
Fam-trastuzumab deruxtecan-nxki, a targeted therapy is antibody drug conjugate (ADC) which is directed for HER2 cancers. It has two parts, humanized anti-HER-2 monoclonal antibody and topoisomerase inhibitor payload “deruxtecan” which are covalently attached through a tetra peptide-based cleavable...